New insider activity at Dynavax ( (DVAX) ) has taken place on August 25, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Scott Dunseth Myers has made a significant investment in Dynavax by purchasing 3,800 shares of the company’s stock, valued at $41,116.
Recent Updates on DVAX stock
Dynavax Technologies recently reported strong Q2 earnings, showcasing a 31% year-over-year increase in net product revenue for HEPLISAV-B, reaching $92 million. This growth is attributed to increased market share in the U.S. adult hepatitis B vaccine market, now at 45%. The company raised its full-year 2025 revenue guidance for HEPLISAV-B, reflecting confidence in its growth trajectory. Significant progress in clinical pipeline programs, including shingles and pandemic influenza vaccines, supports long-term growth strategies. Despite increased SG&A expenses due to strategic investments and a decrease in cash position from a share repurchase program, Dynavax maintains a positive outlook with expectations of further market share expansion and upcoming trial results for its shingles program.
Spark’s Take on DVAX Stock
According to Spark, TipRanks’ AI Analyst, DVAX is a Neutral.
Dynavax’s overall stock score reflects a mixed financial performance with profitability challenges, a neutral technical outlook, and a challenging valuation due to a negative P/E ratio. However, the positive earnings call and promising corporate events, such as the shingles vaccine trial results, provide a boost to the score. The company’s strategic focus on growth and market expansion is a positive factor, but profitability and valuation concerns weigh on the overall assessment.
To see Spark’s full report on DVAX stock, click here.
More about Dynavax
YTD Price Performance: -18.60%
Average Trading Volume: 1,652,896
Technical Sentiment Signal: Sell
Current Market Cap: $1.23B